US2004115197A1PendingUtilityA1

Remedies for infant chronic arthritis-relating diseases

48
Priority: Apr 2, 2001Filed: Apr 2, 2002Published: Jun 17, 2004
Est. expiryApr 2, 2021(expired)· nominal 20-yr term from priority
Inventors:Kazuyuki YoshizakiNorihiro NishimotoMasahiro IwamotoSeiji MinotaShumpei YokotaTakako Miyamae
A61P 37/02A61P 43/00A61P 29/00A61P 19/02C07K 16/2866A61K 9/0019A61K 45/06C07K 2317/24A61K 2039/505C07K 2317/14C07K 16/248A61K 39/3955C07K 2317/76A61K 39/395
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A therapeutic agent for chronic arthritides diseases of childhood-related diseases, for example chronic arthritides diseases of childhood, Still's disease and the like, comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

Claims

exact text as granted — not AI-modified
1 . A therapeutic agent for chronic arthritides diseases of childhood-related diseases comprising an interleukin-6 (IL-6) antagonist as an active ingredient.  
     
     
         2 . A therapeutic agent for chronic arthritides diseases of childhood comprising an interleukin-6 (IL-6) antagonist as an active ingredient.  
     
     
         3 . The therapeutic agent for chronic arthritides diseases of childhood according to  claim 2  wherein the IL-6 antagonist is an antibody against IL-6 receptor.  
     
     
         4 . The therapeutic agent for chronic arthritides diseases of childhood according to  claim 3  wherein the antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.  
     
     
         5 . The therapeutic agent for chronic arthritides diseases of childhood according to  claim 4  wherein the antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.  
     
     
         6 . The therapeutic agent for chronic arthritides diseases of childhood according to  claim 4  wherein the antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.  
     
     
         7 . The therapeutic agent for chronic arthritides diseases of childhood according to any one of  claims 3  to  6  wherein the antibody against IL-6 receptor is a recombinant antibody.  
     
     
         8 . The therapeutic agent for chronic arthritides diseases of childhood according to  claim 5  wherein the monoclonal antibody against human IL-6 receptor is PM-1 antibody.  
     
     
         9 . The therapeutic agent for chronic arthritides diseases of childhood according to  claim 6  wherein the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.  
     
     
         10 . The therapeutic agent for chronic arthritides diseases of childhood according to any one of  claims 3  to  5  wherein the antibody against IL-6 receptor is a chimeric antibody, a humanized antibody, or a human antibody against IL-6 receptor.  
     
     
         11 . The therapeutic agent for chronic arthritides diseases of childhood according to  claim 10  wherein the humanized antibody against IL-6 receptor is humanized PM-1 antibody.  
     
     
         12 . The therapeutic agent for chronic arthritides diseases of childhood according to any one of  claims 2  to  11  wherein said chronic arthritides diseases of childhood are: in the ARA classification, systemic onset, olyarticular, and pauciarticular; in the EULAR classification, systemic onset, polyarticular, and oligoarticular; in the ILAR classification, systemic onset, polyarticular (RF positive), polyarticular (RF negative), oligoarthritis, and extended oligoarthritis; in the classification by the present inventors, primary chronic arthritides of childhood (SPRASH syndrome, idiopathic chronic arthritides of childhood (a. rheumatoid factor (RF)-positive type, b. anti-nuclear antibody (ANA)-positive type, c. RF/ANA-negative type)).  
     
     
         13 . The therapeutic agent for chronic arthritides diseases of childhood according to any one of  claims 2  to  11  wherein said chronic arthritides diseases of childhood are: in the ARA classification, systemic onset and polyarticular; in the EULAR classification, systemic onset and polyarticular; in the ILAR classification, systemic onset, polyarticular (RF positive), polyarticular (RF negative), and extended oligoarthritis; in the classification by the present inventors, primary chronic arthritides of childhood (SPRASH syndrome, idiopathic chronic arthritides of childhood (a. rheumatoid factor (RA)-positive type, b. anti-nuclear antibody (ANA)-positive type)).  
     
     
         14 . The therapeutic agent for chronic arthritides diseases of childhood according to any one of  claims 2  to  11  wherein said chronic arthritides diseases of childhood are: in the ARA classification, systemic onset and polyarticular; in the EULAR classification, systemic onset and polyarticular; in the ILAR classification, systemic onset, polyarticular (RF positive), and extended oligoarthritis; in the classification by the present inventors, primary chronic arthritides of childhood (SPRASH syndrome, idiopathic chronic arthritides of childhood (a. rheumatoid factor (RF)-positive type)).  
     
     
         15 . A therapeutiac agent for Still's disease comprising an interleukin-6 (IL-6) antagonist as an active ingredient.  
     
     
         16 . The therapeutic agent for Still's disease according to  claim 15  wherein an interleukin-6 antagonist is an antibody against IL-6 receptor.  
     
     
         17 . The therapeutic agent for Still's disease according to  claim 16  wherein the antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.  
     
     
         18 . The therapeutic agent for Still's disease according to  claim 17  wherein the antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.  
     
     
         19 . The therapeutic agent for Still's disease according to  claim 17  wherein the antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.  
     
     
         20 . The therapeutic agent for Still's disease according to any one of  claims 16  to  19  wherein the antibody against IL-6 receptor is a recombinant antibody.  
     
     
         21 . The therapeutic agent for Still's disease according to  claim 18  wherein the monoclonal antibody against human IL-6 receptor is PM-1 antibody.  
     
     
         22 . The therapeutic agent for Still's disease according to  claim 19  wherein the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.  
     
     
         23 . The therapeutic agent for Still's disease according to any one of  claims 16  to  18  wherein the antibody against IL-6 receptor is a chimeric antibody, a humanized antibody, or a human antibody against IL-6 receptor.  
     
     
         24 . The therapeutic agent for Still's disease according to  claim 23  wherein the humanized antibody against IL-6 receptor is humanized PM-1 antibody.  
     
     
         25 . The therapeutic agent for Still's disease according to any one of  claims 15  to  24  wherein Still's disease is adult Still's disease.  
     
     
         26 . The therapeutic agent for Still's disease according to any one of  claims 15  to  24  wherein Still's disease is Still's disease of children.

Join the waitlist — get patent alerts

Track US2004115197A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.